Relay Therapeutics (RLAY) EPS (Weighted Average and Diluted) (2021 - 2026)
Relay Therapeutics (RLAY) reported EPS (Weighted Average and Diluted) of -$0.41 for Q1 2026, up 10.87% year-over-year from -$0.37 in Q1 2025, and down 32.26% quarter-over-quarter from -$0.31 in Q4 2025.
Relay Therapeutics (RLAY) EPS (Weighted Average and Diluted) (2021 - 2026) Analysis & Trends
Relay Therapeutics (RLAY) has 6 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.41 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.41, up 10.87% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.56 (up 29.09% YoY), and the FY2025 annual result was -$1.61, up 31.78% from the prior year.
- EPS (Weighted Average and Diluted) slipped to -$0.41 in Q1 2026 per RLAY's latest filing, from -$0.31 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at -$0.31 in Q4 2025 and troughed at -$0.81 in Q2 2023.
- A 5-year average of -$0.57 and a median of -$0.57 in 2022 frame the typical range for EPS (Weighted Average and Diluted).
- The sharpest annual moves came in 2023 and 2025: EPS (Weighted Average and Diluted) sank 36.84% in 2023, then soared 40.58% in 2025.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.55 in 2022, then retreated by 21.82% to -$0.67 in 2023, then surged by 37.31% to -$0.42 in 2024, then rose by 26.19% to -$0.31 in 2025, then slumped by 32.26% to -$0.41 in 2026.
- Business Quant data shows RLAY's EPS (Weighted Average and Diluted) at -$0.41 in Q1 2026, -$0.31 in Q4 2025, and -$0.43 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Relay Therapeutics | 2.86 Bn | 2.86 Bn | - | -0.41 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.41 |
| Dec 31, 2025 | -0.31 |
| Sep 30, 2025 | -0.43 |
| Jun 30, 2025 | -0.41 |
| Mar 31, 2025 | -0.46 |
| Dec 31, 2024 | -0.42 |
| Sep 30, 2024 | -0.63 |
| Jun 30, 2024 | -0.69 |
| Mar 31, 2024 | -0.62 |
| Dec 31, 2023 | -0.67 |
| Sep 30, 2023 | -0.54 |
| Jun 30, 2023 | -0.81 |
| Mar 31, 2023 | -0.78 |
| Dec 31, 2022 | -0.55 |
| Sep 30, 2022 | -0.76 |
| Jun 30, 2022 | -0.71 |
| Mar 31, 2022 | -0.57 |
| Dec 31, 2021 | -0.62 |
| Sep 30, 2021 | -0.66 |